Lung cancer combo shows promise in slowing tumor growth
NCT ID NCT03909334
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding ramucirumab to the standard drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their disease worsening. About 160 patients will receive either the combination or osimertinib alone. The study aims to see if the combo improves progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Osimertinib (Tagrisso) and ramucirumab (Cyramza)
What this could lead to
If successful, this combination could delay cancer progression longer than osimertinib alone, offering a new first-line option for EGFR-mutant lung cancer.
What could go wrong
This is a mid-stage trial with 160 participants, so results may not confirm benefit. Adding ramucirumab also raises risks like high blood pressure, bleeding, or blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Georgetown University
Washington D.C., District of Columbia, 20057, United States
-
Indiana Univesity Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
New York University Cancer Center
New York, New York, 10016, United States
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Summit Medical Group, PA
Berkeley Heights, New Jersey, 07922, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States